It was also concluded that an ePLND should not be avoided in men with intermediate or high-risk prostate cancer and preoperative negative 18F-PSMA-1007 PET/CT, as 20% have microscopic lymph node metastasis [50]. This evidence concerns the gene FOLH1 and prostate cancer.